Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

ion or $0.32 per share.

As of September 30, 2008, the Company held cash, cash equivalents and investments of $67.9 million.

Year-to-Date 2008 Financial Results

Collaborative and other research and development revenues were $22.3 million for the nine months ended September 30, 2008, compared to $43.1 million for the nine months ended September 30, 2007. This decrease is driven by a reduction in peramivir related clinical development costs leading to a reduction in costs and associated revenue from HHS, plus the $4.9 million reserve taken in the second quarter of 2008 for amounts BioCryst previously expected to receive from HHS related to costs incurred in the Phase 3 program in intramuscular peramivir for outpatient influenza. These costs were associated with the Phase 3 program for peramivir that was voluntarily discontinued earlier this year and reimbursement of these costs is under discussion with HHS.

R&D expenses were $51.3 million for the nine months ended September 30, 2008, compared to $64.9 million for the nine months ended September 30, 2007. The decrease in R&D expenses is due to a reduction in the clinical development costs and toxicology costs associated with the peramivir program and a reduction in manufacturing costs associated with both the peramivir and forodesine HCl programs. These reductions were partially offset by an increase in the Company's clinical development costs for forodesine HCl and increases in personnel related costs and professional services.

G&A expenses were $8.0 million for the nine months ended September 30, 2008, compared to $7.0 million for the nine months ended September 30, 2007. The higher expenses were primarily due to an increase in professional fees and personnel related costs.

The net loss for the nine months ended September 30, 2008 was $34.8 million, or $0.91 per share, compared to a net loss for the nine months ended September 30, 2007 of $26.8 million or $0.86 per share.


'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... MIAMI (PRWEB) March 02, 2015 ... a newly formed alliance with Shenzhen HANK Bioengineering ... M.D., Ph.D. The alliance will establish a stem ... Guangdong Province, China in September 2015. , Shenzhen ... by Zhang, an award-winning scientist, microbiologist and virologist, ...
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: ... release disseminated this morning by PR Web, and redistributed ... release states that Immunovaccine has entered into a co-development ... did not originate from Immunovaccine and there is no ... Please note that all official statements by Immunovaccine ...
(Date:2/27/2015)... , Feb. 27, 2015 Research and Markets ... "Global Market Report of Trypsin" report to their offering. ... 9002-07-7) aims at providing comprehensive data on Trypsin globally and ... , North America , Latin ... close attention to Trypsin This report focuses on ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2
... managed, with the help of an advanced X-ray flash, to ... that has been recognised by the journal Science . ... home to one of the world,s most advanced particle accelerators, ... and study life,s tiniest components: atoms, molecules and proteins. ...
... PLYMOUTH MEETING, Pa. , May 10 /PRNewswire-Asia-FirstCall/ -- ... announced,financial results for the first quarter ended March 31, 2010 . ... ... was a,quarter of successful management transition at Sunstone. We replaced senior,managers including ...
... Fla. , May 10 Dyadic International, Inc. ... today that its President and Chief Executive Officer, Mark ... Renshaw 6th Annual Global Healthcare Conference in London, England ... 11:05 a.m. local time ( 6:05 a.m. EDT ). ...
Cached Biology Technology:BMP Sunstone Reports First Quarter 2010 Financial Results 2BMP Sunstone Reports First Quarter 2010 Financial Results 3BMP Sunstone Reports First Quarter 2010 Financial Results 4BMP Sunstone Reports First Quarter 2010 Financial Results 5BMP Sunstone Reports First Quarter 2010 Financial Results 6BMP Sunstone Reports First Quarter 2010 Financial Results 7BMP Sunstone Reports First Quarter 2010 Financial Results 8BMP Sunstone Reports First Quarter 2010 Financial Results 9BMP Sunstone Reports First Quarter 2010 Financial Results 10BMP Sunstone Reports First Quarter 2010 Financial Results 11BMP Sunstone Reports First Quarter 2010 Financial Results 12Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference 2
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite a ... from industries such as consumer electronics, automotive, storage ... surface mount technology (SMT) screen printers. Innovations in ... control will push the adoption curve up. Meanwhile, ... steady as glue dispensers are indispensable in the ...
(Date:1/22/2015)... TORONTO , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the ... announced the launch of its new website design. ... in its infancy", says Peter O,Neill , founder and ... ever, the industry needs involvement from the key players on ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... F. Laurance, senior staff scientist at the Smithsonian Tropical ... the Institute and Biodiversity Chair at the H. John ... have won the coveted 2008 BBVA Foundation Frontiers of ... 30 Jan. 2009 in Madrid, Spain. , ...
... deposited iron in the Southern Ocean has filled in ... in locking atmospheric carbon dioxide (CO2) in the ocean. ... Raymond Pollard of the National Oceanography Centre, Southampton, and ... Hole Oceanographic Institution (WHOI), found that natural iron fertilization ...
... many studies refuting the claim of a link between vaccines ... issue of Clinical Infectious Diseases and now available ... epidemiological and biological studies refute these claims. "When one ... springs up to take its place," said study author Paul ...
Cached Biology News:Smithsonian scientists receive coveted BBVA Ecology and Conservation Award 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 3Vaccines and autism: Many hypotheses, but no correlation 2
... automated microplate strip washer for 96- and 384-well ... strip washing capability, the Columbus combines high flexibility ... , Features ,Key features ... or 16 channels, crosswise aspiration, overflow and bottom ...
... solution for all plate washing needs in both ... ,The PW 384 provides an excellent solution for ... Discovery (Assay development, Screening or Lead Optimization) and ... ,The PW 384 has set a standard for ...
... Protein:Protein Interaction Reagent A powerful new ... gained traction as an in vitro method ... of publications feature the exclusive Pierce ProFound ... a variety of issues relating to protein ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Biology Products: